Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by itntdfon Jan 11, 2023 8:57pm
263 Views
Post# 35217309

is it or isn't it?

is it or isn't it?the license, development, supply and distribution agreement signed nov. 16, 2017, took great pains to say the following:

27.
NATURE OF THIS AGREEMENT
27.1
The Parties are independent contractors and none of the provisions of this Agreement shall be deemed to constitute a partnership or joint venture between the Parties. Neither Party shall have any authority to bind the other in any way.

 
Yet, in the January, 2023 Investor Presentation, oncy states:
 
Successful partnership with Adlai Nortye
China, Hong Kong, Macau, Singapore, South Korea
and Taiwan
Upfront and milestone payments of up to $86.6M
$21M in milestone payments largely under
Oncolytics’ control, with double-digit royalties
$65M tied to potential development expansion

wonder why?  is it a partnership or isn't it?  a partnership certainly has legal ramifications so wonder if there was some confidential change to the agreement.  there are certainly a number of confidential provisions in the agreement, maybe this was changed without notification.

seems odd.
<< Previous
Bullboard Posts
Next >>